Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real-World Study [0.03%]
贝卢莫司 Dil 在重度预处理的长期慢性移植物抗宿主病管理中的应用：一项回顾性的多中心真实世界研究
Ben Varon,Ron Ram,Avichai Shimoni et al.
Ben Varon et al.
Chronic graft-versus-host disease (cGVHD) is the primary contributor to morbidity and mortality following allogeneic stem cell transplantation (ASCT). Belumosudil, a ROCK2 inhibitor, was approved for the cGVHD treatment after at least two p...
Multicenter Study
Hematological oncology. 2026 Jul;44(4):e70202. DOI:10.1002/hon.70202 2026
Real-World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States [0.03%]
美国布鲁顿酪氨酸激酶抑制剂治疗套细胞淋巴瘤的现实世界治疗模式和卫生资源利用状况
Bijal Shah,Mei Xue,Wesley Furnback et al.
Bijal Shah et al.
The introduction of Bruton tyrosine kinase inhibitors (BTKis) to the mantle cell lymphoma (MCL) treatment paradigm has shown promising results for patient outcomes. However, insufficient real-world evidence remains to compare the outcomes o...
Thrombosis in Low-Risk Polycythemia Vera: Insights From a Large Real-World Cohort [0.03%]
低风险真性红细胞增多症血栓形成的机制——来自大规模真实世界队列的见解
Inbar Cohen,Alon Rozental,Pia Raanani et al.
Inbar Cohen et al.
Polycythemia vera (PV) is a myeloproliferative neoplasm driven by JAK2 mutations and associated with thrombotic complications. Current risk stratification classifies younger patients without prior thrombosis as low-risk (LR), yet long-term ...
Francesco Tarantini,Cosimo Cumbo,Luisa Anelli et al.
Francesco Tarantini et al.
Incidence and Survival of Patients With Angioimmunoblastic T-Cell Lymphoma: A Nationwide Population-Based Study Using English Cancer Registration Data [0.03%]
基于英国癌症登记数据的血管免疫母T细胞淋巴瘤患者的流行病学及生存研究
Sarah J Halligan,Christopher P Fox,Matthew J Grainge et al.
Sarah J Halligan et al.
Angioimmunoblastic T-cell lymphoma (AITL) is a rare, aggressive subtype of peripheral T-cell lymphoma. Whole population studies of AITL are infrequent and often grouped along with other T-cell lymphomas. We undertook a population-based stud...
Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia [0.03%]
诱导治疗后完全缓解与部分缓解伴血液学改善的急性髓系白血病患者采用地西他滨和维奈托克联合用药方案的效果：一项随机、3 期试验
Georgio Medawar,Jean-Sebastien Anoma,Elizabeth Hill et al.
Georgio Medawar et al.
The optimal duration of hypomethylating agent (HMA) therapy combined with venetoclax (Ven) in newly diagnosed acute myeloid leukemia (ND-AML) remains uncertain. Standard of care (SOC) uses 5-day decitabine (Dec-5) or 7-day azacitidine (Aza-...
Comparative Study
Hematological oncology. 2026 May;44(3):e70198. DOI:10.1002/hon.70198 2026
Sequential BV-AVD Therapy in Richter Transformation: Insights Into the Management of Elderly Patients [0.03%]
序贯BV-AVD方案治疗Richter转化的疗效分析及老年患者管理策略探讨
Arianna Bevilacqua,Alessandro Cellini,Nicolò Danesin et al.
Arianna Bevilacqua et al.
Hodgkin-variant Richter's transformation (HvRT) is a rare evolution of chronic lymphocytic leukemia (CLL) into a lymphoma with histological characteristics akin to those of classical Hodgkin lymphoma (cHL), overall occurring in < 1% of CLL ...
Case Reports
Hematological oncology. 2026 May;44(3):e70197. DOI:10.1002/hon.70197 2026
Long-Term Follow-Up of Chidamide With Chemotherapy in Untreated Peripheral T-Cell Lymphoma: One Single Center Real-World Study in China [0.03%]
中国单中心复发/难治外周T细胞淋巴瘤初治患者口服柴塞米联合化疗长期随访研究
Jiajie He,Fan Xia,Lingzi Yu et al.
Jiajie He et al.
Peripheral T-cell lymphoma (PTCL) remains a formidable challenge in clinical management. Histone deacetylase inhibitor chidamide has demonstrated its anti-tumor effects in real-world studies in relapsed or refractory PTCL. To evaluate the e...
The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial [0.03%]
中枢神经系统预防在弥漫大B细胞淋巴瘤中的疗效和毒性：一项随机、多中心、前瞻性三期临床试验（CLSG-CNS-01）
H Mocikova,L Gaherova,T Jancarkova et al.
H Mocikova et al.
The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B-cell lymphoma (DLBCL). Treat...
Clinical Trial
Hematological oncology. 2026 May;44(3):e70193. DOI:10.1002/hon.70193 2026
Zanubrutinib in Hairy Cell Leukemia Variant: Clinical Report and Overview of BTK Inhibition in Variant Disease [0.03%]
扎鲁司特用于治疗毛细胞白血病变异型：临床报道及BTK抑制在变异型疾病中的概述
A Bernardelli,E Carazzai,I Mion et al.
A Bernardelli et al.
Hairy cell leukemia variant (HCL-v) is a rare B-cell malignancy with limited treatment options in relapsed or refractory settings. We describe the first reported case of chemo-refractory HCL-v successfully treated with zanubrutinib monother...
Case Reports
Hematological oncology. 2026 May;44(3):e70194. DOI:10.1002/hon.70194 2026